Result Number | Material Type | Add to My Shelf Action | Record Details and Options |
---|---|---|---|
1 |
Material Type: Article
|
![]() |
BNT162b vaccines protect rhesus macaques from SARS-CoV-2Nature (London), 2021-04, Vol.592 (7853), p.283-289 [Peer Reviewed Journal]Copyright Nature Publishing Group Apr 8, 2021 ;ISSN: 0028-0836 ;EISSN: 1476-4687 ;DOI: 10.1038/s41586-021-03275-y ;PMID: 33524990Full text available |
2 |
Material Type: Article
|
![]() |
Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 VariantNew England Journal of Medicine, 2021-05, Vol.384 (20), p.1885-1898 [Peer Reviewed Journal]Copyright © 2021 Massachusetts Medical Society. All rights reserved. ;Copyright © 2021 Massachusetts Medical Society. ;COPYRIGHT 2021 Massachusetts Medical Society ;2021. Not withstanding the ProQuest Terms and Conditions, you may use this content in accordance with the associated terms available at https://www.nejm.org/about-nejm/permissions?query=footer ;Copyright © 2021 Massachusetts Medical Society. All rights reserved. 2021 Massachusetts Medical Society ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa2102214 ;PMID: 33725432Digital Resources/Online E-Resources |
3 |
Material Type: Article
|
![]() |
Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control studyBMJ (Online), 2021-05, Vol.373, p.n1088-n1088 [Peer Reviewed Journal]Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. ;Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. ;2021 Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. BMJ This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ . Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. 2021 BMJ ;ISSN: 1756-1833 ;ISSN: 0959-8138 ;EISSN: 1756-1833 ;DOI: 10.1136/bmj.n1088 ;PMID: 33985964Full text available |
4 |
Material Type: Article
|
![]() |
Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7Nature (London), 2021-05, Vol.593 (7857), p.130-135 [Peer Reviewed Journal]Copyright Nature Publishing Group May 6, 2021 ;ISSN: 0028-0836 ;EISSN: 1476-4687 ;DOI: 10.1038/s41586-021-03398-2 ;PMID: 33684923Full text available |
5 |
Material Type: Article
|
![]() |
SARS-CoV-2 breakthrough infections in vaccinated individuals: measurement, causes and impactNature reviews. Immunology, 2022-01, Vol.22 (1), p.57-65 [Peer Reviewed Journal]2021. Springer Nature Limited. ;COPYRIGHT 2022 Nature Publishing Group ;Springer Nature Limited 2021. ;Springer Nature Limited 2021 ;ISSN: 1474-1733 ;EISSN: 1474-1741 ;DOI: 10.1038/s41577-021-00662-4 ;PMID: 34876702Full text available |
6 |
Material Type: Article
|
![]() |
Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infectionNature medicine, 2021-11, Vol.27 (11), p.2032-2040 [Peer Reviewed Journal]2021. The Author(s). ;COPYRIGHT 2021 Nature Publishing Group ;The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;The Author(s) 2021 ;ISSN: 1078-8956 ;EISSN: 1546-170X ;DOI: 10.1038/s41591-021-01540-1 ;PMID: 34588689Full text available |
7 |
Material Type: Article
|
![]() |
Heterologous prime-boost COVID-19 vaccination: initial reactogenicity dataThe Lancet (British edition), 2021-05, Vol.397 (10289), p.2043-2046 [Peer Reviewed Journal]2021 Elsevier Ltd ;2021. Elsevier Ltd ;2021 Elsevier Ltd. All rights reserved. 2021 Elsevier Ltd ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(21)01115-6 ;PMID: 33991480Full text available |
8 |
Material Type: Article
|
![]() |
Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trialThe Lancet (British edition), 2022-01, Vol.399 (10321), p.237-248 [Peer Reviewed Journal]2022 Elsevier Ltd ;Copyright © 2022 Elsevier Ltd. All rights reserved. ;2022. Elsevier Ltd ;2021 Elsevier Ltd. All rights reserved. 2022 Elsevier Ltd ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(21)02753-7 ;PMID: 34953526Full text available |
9 |
Material Type: Article
|
![]() |
A pooled testing strategy for identifying SARS-CoV-2 at low prevalenceNature (London), 2021-01, Vol.589 (7841), p.276-280 [Peer Reviewed Journal]COPYRIGHT 2021 Nature Publishing Group ;Copyright Nature Publishing Group Jan 14, 2021 ;ISSN: 0028-0836 ;ISSN: 1476-4687 ;EISSN: 1476-4687 ;DOI: 10.1038/s41586-020-2885-5 ;PMID: 33086375Full text available |
10 |
Material Type: Article
|
![]() |
Myocarditis With COVID-19 mRNA VaccinesCirculation (New York, N.Y.), 2021-08, Vol.144 (6), p.471-484 [Peer Reviewed Journal]2021 American Heart Association, Inc. 2021 ;ISSN: 0009-7322 ;EISSN: 1524-4539 ;DOI: 10.1161/CIRCULATIONAHA.121.056135 ;PMID: 34281357Full text available |
11 |
Material Type: Article
|
![]() |
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19New England Journal of Medicine, 2021-06, Vol.384 (23), p.2187-2201 [Peer Reviewed Journal]Copyright © 2021 Massachusetts Medical Society. All rights reserved. ;Copyright © 2021 Massachusetts Medical Society. ;COPYRIGHT 2021 Massachusetts Medical Society ;2021. Not withstanding the ProQuest Terms and Conditions, you may use this content in accordance with the associated terms available at https://www.nejm.org/about-nejm/permissions?query=footer ;Copyright © 2021 Massachusetts Medical Society. All rights reserved. 2021 Massachusetts Medical Society ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa2101544 ;PMID: 33882225Digital Resources/Online E-Resources |
12 |
Material Type: Article
|
![]() |
Dynamic Public Health Surveillance to Track and Mitigate the US COVID-19 Epidemic: Longitudinal Trend Analysis StudyJournal of medical Internet research, 2020-12, Vol.22 (12), p.e24286-e24286 [Peer Reviewed Journal]Lori Ann Post, Tariq Ziad Issa, Michael J Boctor, Charles B Moss, Robert L Murphy, Michael G Ison, Chad J Achenbach, Danielle Resnick, Lauren Nadya Singh, Janine White, Joshua Marco Mitchell Faber, Kasen Culler, Cynthia A Brandt, James Francis Oehmke. Originally published in the Journal of Medical Internet Research (http://www.jmir.org), 03.12.2020. ;Copyright Gunther Eysenbach MD MPH, Associate Professor Dec 2020 ;Lori Ann Post, Tariq Ziad Issa, Michael J Boctor, Charles B Moss, Robert L Murphy, Michael G Ison, Chad J Achenbach, Danielle Resnick, Lauren Nadya Singh, Janine White, Joshua Marco Mitchell Faber, Kasen Culler, Cynthia A Brandt, James Francis Oehmke. Originally published in the Journal of Medical Internet Research (http://www.jmir.org), 03.12.2020. 2020 ;ISSN: 1438-8871 ;ISSN: 1439-4456 ;EISSN: 1438-8871 ;DOI: 10.2196/24286 ;PMID: 33216726Full text available |
13 |
Material Type: Article
|
![]() |
Persistent Circulating Severe Acute Respiratory Syndrome Coronavirus 2 Spike Is Associated With Post-acute Coronavirus Disease 2019 SequelaeClinical infectious diseases, 2023-02, Vol.76 (3), p.e487-e490 [Peer Reviewed Journal]The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. ;The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com 2022 ;ISSN: 1058-4838 ;EISSN: 1537-6591 ;DOI: 10.1093/cid/ciac722 ;PMID: 36052466Full text available |
14 |
Material Type: Article
|
![]() |
Considerations in boosting COVID-19 vaccine immune responsesThe Lancet (British edition), 2021-10, Vol.398 (10308), p.1377-1380 [Peer Reviewed Journal]2021 World Health Organization. Published by Elsevier Ltd/Inc/BV. All rights reserved. ;2021. World Health Organization. Published by Elsevier Ltd/Inc/BV. All rights reserved. ;Distributed under a Creative Commons Attribution 4.0 International License ;2021 World Health Organization. Published by Elsevier Ltd/Inc/BV. All rights reserved. 2021 ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(21)02046-8 ;PMID: 34534516Full text available |
15 |
Material Type: Article
|
![]() |
Seasonal coronavirus protective immunity is short-lastingNature medicine, 2020-11, Vol.26 (11), p.1691-1693 [Peer Reviewed Journal]COPYRIGHT 2020 Nature Publishing Group ;The Author(s), under exclusive licence to Springer Nature America, Inc. 2020. ;ISSN: 1078-8956 ;ISSN: 1546-170X ;EISSN: 1546-170X ;DOI: 10.1038/s41591-020-1083-1 ;PMID: 32929268Full text available |
16 |
Material Type: Article
|
![]() |
Protection against SARS-CoV-2 after Covid-19 Vaccination and Previous InfectionNew England Journal of Medicine, 2022-03, Vol.386 (13), p.1207-1220 [Peer Reviewed Journal]Copyright © 2022 Massachusetts Medical Society. All rights reserved. ;Copyright © 2022 Massachusetts Medical Society. ;COPYRIGHT 2022 Massachusetts Medical Society ;2022. Not withstanding the ProQuest Terms and Conditions, you may use this content in accordance with the associated terms available at https://www.nejm.org/about-nejm/permissions?query=footer ;Copyright © 2022 Massachusetts Medical Society. All rights reserved. 2022 Massachusetts Medical Society ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa2118691 ;PMID: 35172051Digital Resources/Online E-Resources |
17 |
Material Type: Article
|
![]() |
Model-informed COVID-19 vaccine prioritization strategies by age and serostatusScience, 2021-02, Vol.371 (6532) [Peer Reviewed Journal]2021. This work is published under https://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;DOI: 10.1126/science.abe6959Digital Resources/Online E-Resources |
18 |
Material Type: Article
|
![]() |
Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational studyThe lancet oncology, 2021-06, Vol.22 (6), p.765-778 [Peer Reviewed Journal]2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license ;Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved. ;2021. The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. This work is published under https://creativecommons.org/licenses/by/3.0/ (theLicense”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license 2021 ;ISSN: 1470-2045 ;EISSN: 1474-5488 ;DOI: 10.1016/S1470-2045(21)00213-8 ;PMID: 33930323Full text available |
19 |
Material Type: Article
|
![]() |
Seroconversion rates following COVID-19 vaccination among patients with cancerCancer cell, 2021-08, Vol.39 (8), p.1081-1090.e2 [Peer Reviewed Journal]2021 Elsevier Inc. ;Copyright © 2021 Elsevier Inc. All rights reserved. ;2021 Elsevier Inc. 2021 Elsevier Inc. ;ISSN: 1535-6108 ;EISSN: 1878-3686 ;DOI: 10.1016/j.ccell.2021.06.002 ;PMID: 34133951Full text available |
20 |
Material Type: Article
|
![]() |
COVID-19 vaccines: where we stand and challenges aheadCell death and differentiation, 2021-02, Vol.28 (2), p.626-639 [Peer Reviewed Journal]The Author(s), under exclusive licence to ADMC Associazione Differenziamento e Morte Cellulare 2021. ;The Author(s), under exclusive licence to ADMC Associazione Differenziamento e Morte Cellulare 2021 ;ISSN: 1350-9047 ;EISSN: 1476-5403 ;DOI: 10.1038/s41418-020-00720-9 ;PMID: 33479399Full text available |